Meeting
2021 ASCO Annual Meeting
PD-L1 expression and TOP3A mutation as prognostic factors for adjuvant chemotherapy in triple negative breast cancer.
Authors
Xue Wang
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Xue Wang , Peng Yuan , Feng Du , Lina Cui , Fangchao Zheng , Jian Yue , Bei Zhang , Jiayu Wang , Ying Fan , Fei Ma , Binghe Xu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 541)
DOI
10.1200/JCO.2021.39.15_suppl.541
Abstract #
541
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Tumor infiltrating lymphocytes to predict DFS from intense dose-dense (idd) EPC regimen: Results from the German Adjuvant Intergroup Node-positive study (GAIN-1).
First Author: Aurelia Noske
Poster
2021 ASCO Annual Meeting
Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression.
First Author: Ignacio Ortego
Poster
2020 ASCO Virtual Scientific Program
PREDIX II HER2: Improving pre-operative systemic therapy for human epidermal growth factor receptor 2 (HER2) amplified breast cancer (BC).
First Author: Renske Kornalijnslijper-Altena
Poster
2019 ASCO Annual Meeting
ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early-stage triple-negative breast cancer.
First Author: Heather L. McArthur